Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Avijeet S Chopra, Dusica Hadzi Boskovic, Amit Kulkarni & Jeffrey M Cochran. (2023) Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach. ClinicoEconomics and Outcomes Research 15, pages 375-386.
Read now
Read now
Ziyi Lin & Jianwei Xuan. (2020) Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China. Expert Review of Pharmacoeconomics & Outcomes Research 20:5, pages 549-557.
Read now
Read now
Tansel Comoglu & Emine Dilek Ozyilmaz. (2019) Orally disintegrating tablets and orally disintegrating mini tablets – novel dosage forms for pediatric use. Pharmaceutical Development and Technology 24:7, pages 902-914.
Read now
Read now
Jingping Zhao, Kaida Jiang, Qingwei Li, Yanlei Zhang, Yan Cheng, Ziyi Lin & Jianwei Xuan. (2019) Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China. Journal of Medical Economics 22:5, pages 439-446.
Read now
Read now
Junwen Zhou, Aurélie Millier, Clément François, Samuel Aballéa & Mondher Toumi. (2019) Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Myrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, Christophe Sapin, Amy M Duhig & Leslie Citrome. (2018) Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and Outcomes Research 10, pages 443-456.
Read now
Read now
Junwen Zhou, Aurélie Millier & Mondher Toumi. (2018) Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Tzahit Simon-Tuval, Peter J. Neumann & Dan Greenberg. (2016) Cost-effectiveness of adherence-enhancing interventions: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 16:1, pages 67-84.
Read now
Read now
Thomas R. Einarson & Michiel E. H. Hemels. (2013) Validation of an economic model of paliperidone palmitate for chronic schizophrenia. Journal of Medical Economics 16:11, pages 1267-1274.
Read now
Read now
Articles from other publishers (15)
Yasuharu Kashiwagura, Shota Takusagawa, Yasuyuki Ikematsu, Shimako Tanaka, Noriyuki Namiki & Shinya Uchida. (2023) Tablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods. Acta Pharmaceutica 73:1, pages 107-119.
Crossref
Crossref
Xiuru Su, Long Zhao, Yujie Shang, Yingnan Chen, Xiaowen Liu, Xuan Wang, Meihong Xiu, Huijing Yu & Lijun Liu. (2022) Repetitive transcranial magnetic stimulation for psychiatric symptoms in long-term hospitalized veterans with schizophrenia: A randomized double-blind controlled trial. Frontiers in Psychiatry 13.
Crossref
Crossref
Marjanne A. Piena, Natalie Houwing, Carla W. Kraan, Xiaofeng Wang, Heidi Waters, Ruth A. Duffy, Suresh Mallikaarjun & Craig Bennison. (2021) An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia. PharmacoEconomics 40:1, pages 121-131.
Crossref
Crossref
Mohammadali Poursharifi Ghourichay, Seyed Hossein Kiaie, Ali Nokhodchi & Yousef Javadzadeh. (2021) Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives. BioMed Research International 2021, pages 1-12.
Crossref
Crossref
Luying Wang, Fenghao Shi, Xin Guan, He Xu, Jing Liu & Hongchao Li. (2021) A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia. Frontiers in Public Health 9.
Crossref
Crossref
Huajie Jin, Stewart Robinson, Wenru Shang, Evanthia Achilla, David Aceituno & Sarah Byford. (2021) Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies. PharmacoEconomics 39:7, pages 757-770.
Crossref
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, David Aceituno & Sarah Byford. (2020) Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia. PLOS ONE 15:7, pages e0234996.
Crossref
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno & Sarah Byford. (2020) A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. PharmacoEconomics 38:6, pages 537-555.
Crossref
Crossref
Emine Tashan, Alptug Karakucuk & Nevin Celebi. (2020) Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation. AAPS PharmSciTech 21:3.
Crossref
Crossref
Iara Carolina Barbosa Henrique, Tácio Lima, Daniela Oliveira Melo & Patricia Melo Aguiar. (2019) Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 1-15.
Crossref
Crossref
Francesco Cilurzo, Umberto M. Musazzi, Silvia Franzé, Francesca Selmin & Paola Minghetti. (2018) Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements. Drug Discovery Today 23:2, pages 251-259.
Crossref
Crossref
Tarek Turk, Mahmoud Alkhatib, Ghadir Abbas, MHD Khaled Jawish, Omar Mohammad Hammamieh Alshar, Hamza Abou Alchamat & Adib Essali. (2017) Risperidone (oral forms) for people with schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Hoover Quitian Reyes, Jair Alberto Arciniegas Barrera, Adriana Bohórquez Peñaranda & Carlos Gómez Restrepo. (2016) Costo efectividad de los antipsicóticos en el tratamiento de mantenimiento de la esquizofrenia en Colombia. Revista Colombiana de Psiquiatría 45:2, pages 67-74.
Crossref
Crossref
Gregory Kruse, Bruce J. O. Wong, Mei Sheng Duh, Patrick Lefebvre, Marie-Hélène Lafeuille & John M. Fastenau. (2015) Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. PharmacoEconomics 33:10, pages 1049-1067.
Crossref
Crossref
Michael Sonntag, Hans-Helmut König & Alexander Konnopka. (2013) The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review. PharmacoEconomics 31:12, pages 1131-1154.
Crossref
Crossref